We report a thin-layer-chromatographic micro-analysis for quinidine in serum, with detection by fluorescence densitometry. Quinidine is extracted from 20 j.L of serum at pH 13 into 3 mL of hexane/acetone solution (80/20 by vol) containing N-(1-naphthyl)ethylenediamine as internal standard. The extract is concentrated and applied to silica-gel-impregnated plates for conventional thin-layer chromatography. Quinidine is identified from its RF value and quantified from the peakheight ratio between quinidine and the internal standard, relative to that of simultaneously extracted serum standards.
the serum of patients, as measured by the proposed method (x) and by a traditional double-extraction spectrofluorometric assay (y), were related as follows: y = 0.994x + 0.276 (r = 0.989, n = 20).
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Quinidine has been widely used since 1918 as an effective antiarrhythmic agent, and therapeutic monitoring of the drug has been of established value for more than 20 years. It has been measured by spectrofluorometry (1) (2) (3) (4) , thin-layer chromatography (5-8), gas-liquid chromatography (9) , liquid chromatography (10) (11) (12) (13) , and nonisotopic immunoassay (14, 15).
Some fluorometric methods (3, 4) require at least 0.5 mL of sample and thus preclude micro-analysis. Others (1, 2) suffer from interference by inactive metabolites of quinidine, which are particularly prominent in patients with congestive heart failure and (or) poor renal function (16) . Even the popular double-extraction fluorometric analysis of Cramer and Isaksson (3) reportedly gives results approximately 20% greater than do some liquid-chromatographic methods (14). Gas-liquid and liquid chromatographic methods (9) (10) (11) (12) (13) , although very specific, require laborious extractions, large sample volumes, or both. Furthermore, these chromatographic techniques are inherently slow because only one sample can be measured at a time. Homogeneous immunoassays are quickly and easily performed, but the reagents are generally expensive and the assays usually yield results about 25% greater than chromatographic methods because of the cross reactivity of the antibody with dihydroquinidine, (3s)-3-hydroxyquinidine, and quinidine-N-oxide (14, 15). Thin-layer chromatography is both specific and sensitive for measurement of unmetabolized quinidine,
and it has the additional feature of permitting large-scale "batch" analysis.
However, previous thin-layer chromato- 
Materials and Methods

Apparatus
We used commercially available thin-layer chromatography plates, 10cm x 20 cm, coated with 0.25 mm of Silica Gel 60 F254 (EM Reagents, E. Merck, Darmstadt, F.R.G.). Before use the plates were heat-activated (80 #{176}C) and were cut to 10 cm x 10 cm. After sample application, the plates were developed in glass battery jars, then scanned with a densitometer ("Auto Scanner Flur-Vis";
Helena Laboratories, Beaumont, TX 77704) in the fluorescence mode (366-nm excitation) with slit size 0.2 mm x 5 mm, scan speed 0.13 cm/s, and chart speed 1.25 cmls. The "auto-gain" mode was used to set at full scale the most intensely fluorescent spot in each chromatogram.
Reagents and Standards
All reagents were A.R grade. Identify quinidine and NED from their RF values (0.58 and 0.46, respectively), using the standards for comparison. For each sample calculate the peak-height ratio (quinidine:NED). Plot the ratio for each extracted standard against its concentration.
Quantify quinidine in the unknowns and control by using their peak-height ratios and the standard plot.
Results
A standard curve was prepared by supplementing drugfree serum with quinidine. A plot of peak-height ratio (x) vs concentration (y) was linear over the range of eight concentrations studied (0-20 mg/L): y = 8.036x -0.500 (r = 0.996). As little as 0.2 mg of quinidine per liter could be measured in serum. The uncorrected analytical recovery over this concentration range was 60-65%, determined by comparing peak heights of extracted serum standards with those of nonextracted methanolic standards. We corrected for this incomplete recovery by using simultaneously extracted serum standards in each analysis. Serum from 10 drug-free volunteers, taken through the proposed method, showed no interfering peaks in the chromatograms at the RF of either quinidine or NED. The within-run precision was estimated by analysis of drug-free serum supplemented with quinidine to concentrations of 2.5 and 5.0 mgfL, respectively.
The coefficients of variation within-run were 8.6% (2.5 mg/L, n = 12) and 8.5% (5.0 mgI L, n = 12). Between-run precision was estimated by analysis of these sera on each of six days. The between-run coefficients of variation were 5.5% (2.5 mg/L, n = 10) and 3.4% (5.0 mg/L, n = 10). Qumnidine concentrations in serum declined after six days of storage (-20 #{176}C) in the dark.
The developed thin-layer-chromatographic spots were stable for at least 4 h when the plates were stored in the dark. However, when the plates were exposed to light, the peakheight ratios began to decline within 1 h.
We Quinine is an optical isomer of quinidmne, so it will interfere in both the proposed analysis and in spectrofluorometric procedures. However, as an antimalarial agent, it has been largely replaced by other, more efficacious medications. It is present in the beverage tonic ("quinine") water in concentrations ranging from 29 to 80 mg/L (17), but concentrations of quinine in serum 45 mm after ingestion of 240 mL of tonic water are <0.1 mgfL (17), well below the limit of sensitivity of the proposed assay. Therefore this is a negligible source of interference.
Twenty sera from 12 different patients were analyzed on the same days by both the proposed method (x) and a modification of the widely used double-extraction method (y) of Cramer and Isaksson (3) ( Table 1 ). The latter method involves extraction of quinidine from 0.5 mL of serum at alkaline pH into toluene followed by back-extraction into dilute sulfuric acid and spectrofluorometry.
The "leastsquares" regression equation was: y = 0.994x + 0.276 (r = 0.989). In addition to quinicline, these patients were receiv- ing a total of 33 other drugs ( Table 1) , none of which (or their metabolites) interfered.
Discussion
In the proposed assay a micro-volume (20 Although it is not structurally similar to quinidine, we chose to use NED as the internal standard because it has extraction characteristics similar to those of quinidine, has an RF value (0.46) near that (0.58) of quinidine, and exhibits intense fluorescence. Furthermore, it is not a drug. Our finding that quinidine in serum deteriorates after six days of storage (-20 #{176}C) in the dark is in contrast to a previously published report indicating stability in serum for three weeks (20) .
Comparison of results obtained with the proposed method and with the double-extraction fluorescence method showed the latter to yield concentrations that averaged 12% higher (Table 1) . This difference cannot be explained by the reported simultaneous measurement of dihydroquinidine with the double-extraction method (4) because the present chromatographic method did not reveal the presence of dihydroquinidine (at RF 0.52) in any of our patients except for a trace of the compound in patient no.9 (Table 1) , who had the highest quimdine concentration in the series. The lack of measurable dihydroquinidine is consistent with the observation of Powers and Sadee (11), who found that the compound, present as a pharmacologically active contaminant in most commercial quimdine preparations, accounts for only a negligible (<10%) proportion of the total drug in serum. In addition, we noted no other fluorescent spots in the chromatograms of hexane/acetone extracts of sera from our patients.
Our experience with the proposed thin-layer chromatographic micro-analysis of quinidine leadsus to recommend it for routine use in the clinical laboratory, particularly when many samples must be analyzed simultaneously. We gratefully acknowledge the technical assistance of John R.
Briggs.
